Go to Top

Iproteos, is one of the 31 new technological spin-off companies launched in 2011 with support from ACC1Ó, the agency set up by the Catalan Government to promote competitiveness among enterprises.
ACC1Ó fosters the establishment and growth of new technology-based companies in Catalonia, enabling technology transfer from basic research and universities into the business world. This is achieved promoting the generation of new technology-based spin-off companies, which bring new products to the market, or through the incorporation of new technology, through patent license agreements, to an existing company, helping innovation in product and processes.


Angewandte Paper – Roger Prades and Ernest Giralt

Roger Prades, Iproteos CSO, is the first author of an article published this January at Angewandte Chemie reporting a novel peptide capable of overcoming the blood-brain barrier. The work has been possible through the collaboration of a team composed by scientists at IRB Barcelona, RCSI, ISD, INA and UB.

The BBB-shuttle is a retro-enantio peptide that is protease-resistant, non-toxic and has the ability of transporting cargos of distinct sizes and types across this

Read More

“Barcelona city” 2014 prize awarded to Ernest Giralt

Ernest Giralt, co-founder of Iproteos, has been awarded with the “Barcelona City” 2014 prize in the category of Experimental Sciences and Technology. The jury has recognized Prof. Giralt for his development of a technology that allows a cytotoxic peptide from the bee poison to target only tumor cells, without affecting the healthy ones, being therefore, a therapeutic approach with application in chemotherapy.

The award ceremony has taken place today,

Read More

Iproteos participates in a consortium awarded with a “RETOS” grant

The project named “Spark”, which is devoted to the development of a drug (IPR19) for the treatment of the cognitive impairment associated with schizophrenia, has obtained a “RETOS-Colaboración” grant from the Ministry of Economy and Competitiveness of Spain (RTC-2014-1645-1). Iproteos leads the consortium that is composed by the biopharmaceutical company Ascil-Biopharm, the University of the Basque Region (UPV/EHU), the Institute for Research in Biomedicine (IRB Barcelona) and the Centre for Genomic

Read More


BIO-Europe Spring 2015 – March 9-11: See you there!

Iproteos will participate on the BIO-Europe Spring 2015. This 9th edition will be held next March from Monday 9th to Wednesday 11th in Paris.

Over 2000 delegates, representing more than 1,200 companies took part on the previous BIO-Europe Spring conference, which took place in Turin. BIO-Europe events put together biotechs, pharma companies, finance entities, CRO, CMO and others in order to promote industry growth. In this regard, the partnering

Read More

European Venture Summit, 8-9th December

Iproteos has been selected to present at the 8th edition of the European Venture Summit, next 8-9 Dec in Düsseldorf.

The EVS is the leading investment event in Europe for the technological start-ups. In an effort to drive business growth , the meeting puts together innovative ICT, Life Sciences and Cleantech companies with investors and innovation experts.

In total, 120 companies, which have been selected through the European Venture Contests, will

Read More

Lessons learned – 13th of November

On Thursday 13th of November, Teresa Tarragó will participate on the third session of “Lessons Learned: Sharing experiences to boost competitiveness” , a networking meeting for life sciences professionals organized by Biocat and CataloniaBIO.

In this session, entitled “Diferents models d’inversió en empreses biotecnològiques: experiències par a superar obstacles” (Different investing methods in biotech companies: experiences to overcome obstacles), Teresa will explain the experience of Iproteos with crowdfunding as a rising capital method. Apart from Iproteos, other companies will explain to the audience the private funding alternatives that they have

Read More